Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade
Tóm tắt
Steroid-resistant nephrotic syndrome of childhood poses a dilemma in attempting to balance toxicity of medications against long-term prognosis. This report presents our preliminary experience with the novel use of combined mycophenolate mofetil (MMF) and angiotensin blockade (AB) in the treatment of nine children and young adults with focal glomerulosclerosis (FSGS). All patients were steroid resistant and had failed conventional treatment regimens. Prior to the initiation of the MMF-AB protocol, the patients were pre-treated with weekly intravenous methylprednisolone (MP) (15 mg/kg per week) for 4–8 weeks. Angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers were begun when intravascular volume was restored. MMF was given at a dose of 250–500 mg/m2 per day. Proteinuria, as measured by urine protein/creatinine ratios (Up/c), decreased by 43% following MP (P<0.05). After 6 months of MMF-AB protocol, the Up/c was 72% below baseline (P<0.01). This level was maintained for a minimum of 24 months of observation. Similarly, hyperlipidemia, as measured by total cholesterol and triglycerides, improved significantly with treatment (536±163 to 265±70 mg/dl, 447±168 to 230±92 mg/dl, respectively, P<0.01). Our data support the use of MMF and AB for treatment of steroid-resistant FSGS when other conventional treatments have failed and/or induced toxicity.
Tài liệu tham khảo
International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564
Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79
Martinelli R, Okumura AS, Pereira LJ, Rocha H (2001) Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol 16:658–661
Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG (1978) The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213–218
Ichikawa I, Fogo A (1996) Focal segmental glomerulosclerosis. Pediatr Nephrol 10:374–391
Aviles DH, Irwin KC, Dublin LS, Vehaskari VM (1999) Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 13:298–300
Burgess E (1999) Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int [Suppl] 70:S26–S32
Tune BM, Lieberman E, Mendoza SM (1996) Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatr Nephrol 10:772–778
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939–945
Briggs WA, Choi MJ, Scheel PJ (1998) Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213–217
Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G (1997) Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 51:1583–1589
Fujihara CK, De LN, Malheiros I, Antunes GR, Oliveira IB de, Zatz R (2000) Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283–290
Abitbol CL, Zilleruelo G, Freundlich M, Strauss J (1990) Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 116:243–247
Hogg RJ, Portman R, Milliner D, Lemley K, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242–1249
Laverman GD, Navis G, Henning RH, Jong PE de, Zeeuw (2002) Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020–1025
Woolf AS (1997) Multiple causes of human kidney malformations. Arch Dis Child 77:471–474
National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics 98:649–658
National Center for Health Statistics. Centers for Disease Control (1978) NCHS growth curves for children: birth-18 years. Series 11, 165. DHEW publication (PHS) 78:1650. U.S. Government Printing Office, Washington, DC
Hammer LD, Kraemer H, Wilson DM, Ritter PL, Dornbusch SM (1991) Standardized percentile curves of body mass index for children and adolescents. Am J Dis Child 145:259–263
Schwartz G, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571–590
Motulsky H (1995) Intuitive biostatistics, 2nd edn. Oxford University Press, New York, pp 207–262
Srivastava T, Simon SD, Alon US (1999) High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13:13–18
Waldo FB, Benfield MR, Kohaut EC (1998) Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol 12:397–400
Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88
Matsumoto KM, Ito Y, Abe (1990) Effect of methylprednisolone pulse therapy on cellular immunity abnormalities in a patient with lipoid nephrosis. Nephron 56:339–340
Wollheim FA (1984) Acute and long-term complications of corticosteroid pulse therapy. Scand J Rheumatol [Suppl] 54:27–32
Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A (1995) Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 5:1820–1825
Melocoton TL, Kamil ES, Cohen AH, Fine RA (1991) Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis 18:583–588
Gregory MJ, Smoyer WE, Sedman E, Kershaw DB, Valentini RP, Johnson K, Bunchman TE (1996) Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 7:543–549
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56:2220–2226
Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468–475
Silva JMP, Oliveira EA, Marino VS, Oliveira JS, Torres RM, Ribeiro ALP, Simal CJ, Ribeiro MC (2002) Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol 17:169–172
Taal MW, Brenner BM (2000) Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57:1803–1817
Mimran A, Ribstein J (1999) Angiotensin receptor blockers: pharmacology and clinical significance. J Am Soc Nephrol 10 [Suppl 12]: S273–S277
Hori C, Hiraoka M, Yoshikawa N, Tsuzuki K, Yoshida Y, Yoshioka K, Fujisawa K, Tsukahara H, Ohshima Y, Mayumi M (2001) Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis. Nephron 88:313–319
Palmer BF (2002) Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347:1256–1261
Allison AC, Eugui EM (1993) Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5–28
Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357–1359